Anthera Pharmaceuticals Inc. (ANTH) is all set to report top line data from a phase III study of Blisibimod for the treatment of systemic lupus erythematosus, dubbed CHABLIS-SC1, before November 11, 2016.
The top line data from the CHABLIS-SC1 study will include the primary endpoint evaluation, the Systemic Lupus Erythematosus Responder Index (SRI-6) as well as safety and tolerability data from the study.
The clinical trial results can make or break a drug company. Click here for some of the biotech stocks, which are slated to report clinical trial results in the coming months.
ANTH closed Friday’s trading at $2.35, up 11.37%.
The FDA on Friday approved the expanded use of Amgen’s (AMGN) Enbrel to treat pediatric patients aged 4-17 with chronic moderate-to-severe plaque psoriasis.
Enbrel in combination with Methotrexate or used alone is already indicated for rheumatoid arthritis,…